The investment of ₹1,100 crore for the project will be raised from internal accruals and works are expected to be completed ...

Net Interest Income was up by 12% to ₹2,830 crore YoY, having stood at ₹2,525 crore in Q3 FY24, reporting strong core ...

EBITDA declined 4.8% YoY to ₹3,069.4 crore, though EBITDA margin rose by 50 basis points to 13.4% from 12.9% last year.

Revenue from operations grew 10.5% yoy to ₹13,675.4 crore, compared with ₹12,381 crore registered for the same period in Q3 ...

EBITDA rose 30.4% YoY to ₹109.3 crore, as against ₹83.8 crore in the previous year, led by operational efficiencies and robust order execution. EBITDA margin expanded to 21.7%, up from 19.4% in Q3 ...

The industry hopes for more headroom for higher allocations for rural development schemes to pump up sales in smaller towns ...

The company’s revenue for the quarter registered an increase of 116% y-o-y to ₹3,457 Crore as compared to ₹1,596 Crore.

Pfizer India posts ₹127.6 crore net profit in Q3 FY25; that’s 1.9% of ₹130 crore in the same period last year. Revenue from operations decline marginally by 0.4% YoY at ₹538 crore, as against ₹540 ...

The company registered a 28% increase in its December quarter’s Asset Under Management (AUM) at ₹3,98,043 Crore.

The board approved the second interim dividend of ₹5 per share amounting to 100% of face value, amounting to ₹6,290 crore.

The currency has been under pressure, thus stabilizing it involves injecting Rs 600 billion into banks through bond purchases ...

Compared to 86.6250 in the previous session and flirting with the record low of 86.6475 hit almost two weeks ago, the 1-month ...